Enlivex Therapeutics (NASDAQ:ENLV) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Enlivex Therapeutics (NASDAQ:ENLV) from a hold rating to a sell rating in a report issued on Saturday morning.

A number of other brokerages also recently commented on ENLV. HC Wainwright upped their price objective on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $13.00.

Enlivex Therapeutics Price Performance

Shares of ENLV stock opened at $0.90 on Friday. The firm has a fifty day moving average of $1.10 and a two-hundred day moving average of $1.02. The firm has a market cap of $213.64 million, a P/E ratio of -1.64 and a beta of 1.55. Enlivex Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.10.

Institutional Investors Weigh In On Enlivex Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of Enlivex Therapeutics during the 4th quarter worth $33,000. Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics during the third quarter worth $57,000. Invesco Ltd. purchased a new stake in shares of Enlivex Therapeutics during the fourth quarter valued at $43,000. XTX Topco Ltd lifted its holdings in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares during the period. 1.02% of the stock is currently owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.